Insiders who reported open-market trades in the last 12 months at the companies Nikhil Lalwani files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Patrick D. Walsh - $2.32M in ANIP purchases and sales in the last 12 months
Stephen P. Carey - $1.99M in ANIP purchases and sales in the last 12 months
Christopher Mutz - $1.64M in ANIP purchases and sales in the last 12 months
Chad Gassert - $1.31M in ANIP purchases and sales in the last 12 months
Krista Davis - $785K in ANIP purchases and sales in the last 12 months
Ori Gutwerg - $621K in ANIP purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Nikhil Lalwani is a corporate insider, tracked as PRESIDENT & CEO, Director of ANI PHARMACEUTICALS INC (ANIP). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Nikhil Lalwani submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Nikhil Lalwani been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($11.89M) across all tracked filings.
Nikhil Lalwani is PRESIDENT & CEO, Director of ANI PHARMACEUTICALS INC (ANIP). 9 SEC Form 4 filings on record going back to 2024, most recently on 16 September 2026. Most recent open-market trade: sold $383K of ANIP on 16 September 2026. Lifetime open-market sales: $11.89M.
Recent transactions
13
The latest 13 SEC Form 4 transactions reported by Nikhil Lalwani.
InsiderAlpha's records for Nikhil Lalwani go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. 2 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
